

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/617,616
		Filing Date	July 11, 2003
		First Named Inventor	Bore G. RAJU
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	40 pages + 145 references	Attorney Docket Number	342312004800

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <ul style="list-style-type: none">• Form PTO-1449, (original + 3 copy (36 pages total))• 145 References (divided into 15 Volumes each volume containing a coversheet (sent in 3 separate boxes))• Return Receipt Postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP (Customer No. 25226) Nicholas S. Buffinger - 39,124
Signature	
Date	March 8, 2004


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on the date shown below.	
Dated: 3/8/04	Signature: (Mei Y. Leung)



PATENT
Docket No. 342312004800

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on March 8, 2004.


Mei Y. Leung

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Bore G. RAJU et al.

Serial No.: 10/617,616

Filing Date: July 11, 2003

For: N-HYDROXYAMIDE DERIVATIVES
POSSESSING ANTIBACTERIAL
ACTIVITY

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are

not submitted. Copies of foreign documents and non-patent literature are submitted herewith.
The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of __ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does

not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **342312004800**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 8, 2004


Respectfully submitted,

By: 

Nicolás S. Buffinger
Registration No. 39,124

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5816
Facsimile: (650) 494-0792

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 342312004800	Application Number 10/617,616
	Applicant Bore G. RAJU et al	
	Filing Date July 11, 2003	Group Art Unit Not Yet Assigned
	Mailing Date March 8, 2004	



U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	01/24/2002	2002/0010199	Hagmann et al.			
	2.	02/14/2002	2002/0019419	De Laszlo et al.			
	3.	05/30/2002	2002/0065391	Stilz et al.			
	4.	10/03/2002	2002/0143043	Wehner et al.			
	5.	03/06/2003	2003/0045555	Rivera et al.			
	6.	07/20/1999	5,925,659	Patchett et al.			
	7.	02/01/2000	6,020,347	DeLaszlo et al.			
	8.	02/20/2001	6,191,171	DeLaszlo et al.			
	9.	01/22/2002	6,340,678	Matsuhisa et al.			
	10.	03/05/2002	6,353,099	DeLaszlo et al.			
	11.	06/18/2002	6,407,065	Wattanasin et al.			
	12.	07/16/2002	6,420,418	Hagmann et al.			
	13.	08/13/2002	6,432,923	Wattanasin et al.			
	14.	10/15/2002	6,465,513	Grant et al.			
	15.	12/10/2002	6,492,421	Thorsett et al.			
	16.	09/30/2003	6,627,634	Himmelsbach et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	NO
	17.	01/02/1992	EP 0 463 596	Europe				
	18.	12/30/1992	EP 0 520 336	Europe				
	19.	02/02/2000	EP 0 976 722	Europe				
	20.	11/02/2000	EP 1 048 652	Europe				
	21.	04/18/1996	WO 96/10999	WIPO				
	22.	05/23/1996	WO 96/15148	WIPO				

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 342312004800	Application Number 10/617,616
	Applicant Bore G. RAJU et al	
	Filing Date July 11, 2003	Group Art Unit Not Yet Assigned
	Mailing Date March 8, 2004	

	23.	09/26/1996	WO 96/29309	WIPO				
	24.	12/05/1996	WO 96/38471	WIPO				
	25.	05/29/1997	WO 97/18837	WIPO				
	26.	11/06/1997	WO 97/41102	WIPO				
	27.	11/13/1997	WO 97/42179	WIPO				
	28.	04/23/1998	WO 98/16512	WIPO			Abstract	
	29.	07/23/1998	WO 98/31661	WIPO			Abstract	
	30.	09/11/1998	WO 98/39303	WIPO				
	31.	09/11/1998	WO 98/39325	WIPO			Abstract	
	32.	03/11/1999	WO 99/11258	WIPO				
	33.	05/27/1999	WO 99/25685	WIPO				
	34.	06/03/1999	WO 99/26923	WIPO				
	35.	07/08/1999	WO 99/33805	WIPO			Abstract	
	36.	10/21/1999	WO 99/52926	WIPO				
	37.	12/16/1999	WO 99/63937	WIPO				
	38.	12/29/1999	WO 99/67230	WIPO				
	39.	04/20/2000	WO 00/21920	WIPO				
	40.	07/06/2000	WO 00/39081	WIPO				
	41.	07/27/2000	WO 00/43371	WIPO				
	42.	08/31/2000	WO 00/50396	WIPO				
	43.	10/12/2000	WO 00/59878	WIPO				
	44.	10/12/2000	WO 00/59880	WIPO				
	45.	10/12/2000	WO 00/60355	WIPO				
	46.	01/04/2001	WO 01/00616	WIPO			Abstract	
	47.	02/01/2001	WO 01/06984	WIPO				
	48.	02/01/2001	WO 01/07044	WIPO				
	49.	02/01/2001	WO 01/07048	WIPO				
	50.	02/01/2001	WO 01/07052	WIPO				
	51.	02/22/2001	WO 01/12183	WIPO				
	52.	03/01/2001	WO 01/14328	WIPO				

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 342312004800	Application Number 10/617,616
	Applicant Bore G. RAJU et al	
	Filing Date July 11, 2003	Group Art Unit Not Yet Assigned
	Mailing Date March 8, 2004	

	53.	03/08/2001	WO 01/15733	WIPO				
	54.	04/05/2001	WO 01/23376	WIPO				
	55.	05/03/2001	WO 01/30781	WIPO				
	56.	09/27/2001	WO 01/70708	WIPO				
	57.	10/18/2001	WO 01/77104	WIPO			Abstract	
	58.	12/06/2001	WO 01/92253	WIPO				
	59.	01/10/2002	WO 02/02522	WIPO				
	60.	01/31/2002	WO 02/08202	WIPO				
	61.	01/31/2002	WO 02/08206	WIPO				
	62.	01/31/2002	WO 02/08222	WIPO				
	63.	08/22/2002	WO 02/064558	WIPO				
	64.	01/16/2003	WO 03/004460	WIPO				
	65.	01/30/2003	WO 03/007949	WIPO				
	66.	01/30/2003	WO 03/008380	WIPO			Abstract	
	67.	02/13/2003	WO 03/011288	WIPO				

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	68.	Anderson, M.S. et al. (1993) "UDP-N-acetylglucosamine Acyltransferase of <i>Escherichia coli</i> ," <i>J. Biol. Chem.</i> 268(26):19858-19865.
	69.	Archibald, S.C. et al. (2000). "Discovery and Evaluation of Potent, Tyrosine-based $\alpha 4 \beta 1$ Integrin Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 10:997-999.
	70.	Astles, P.C. et al. (2001). "Diamine Containing VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry</i> 9:2195-2202.
	71.	Azzolina, B.A. et al. (2001) "The Cell Wall and Cell Division Gene Cluster in the <i>Mra</i> Operon of <i>Pseudomonas aeruginosa</i> : Cloning, Production, and Purification of Active Enzymes," <i>Protein Expression and Purification</i> 21(3): 393-400.
	72.	Batt, D.G. (2000). "Disubstituted Indazoles as Potent Antagonists of the Integrin $\alpha_4 \beta_3$," <i>J. Med. Chem.</i> 43:41-58.
	73.	Belvisi, L. et al. (2001). "Potent Integrin Antagonists from a Small Library of RGD-Including Cyclic Pseudopeptides," <i>Organic Letters</i> 3(7):1001-1004.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 342312004800	Application Number 10/617,616
		Applicant <div style="text-align: center;">Bore G. RAJU et al</div>	
		Filing Date July 11, 2003	Group Art Unit Not Yet Assigned
		Mailing Date March 8, 2004	
	74.	Bianchi, E. et al. (2000). "Integrin LFA-1 Interacts with the Transcriptional Co-Activator JAB1 to Modulate AP-1 Activity," <i>Nature</i> 404:617-621.	
	75.	Blythin, D.J. et al. (1994). "Synthesis of Racemic <i>cis</i> - and <i>trans</i> -3-Phenylazetidine-2-Carboxylic Acids as Conformationally Restricted Analogs of Phenylalanine," <i>J. Org. Chem.</i> 59:6098-6100.	
	76.	Boer, J. et al. (2001). "Design and Synthesis of Potent and Selective $\alpha_4\beta_7$ Integrin Antagonists," <i>J. Med. Chem.</i> 44(16):2586-2592.	
	77.	Chang, L.L. et al. (2002). "The Discovery of Small Molecule Carbamates as Potent Dual $\alpha_4\beta_1/\alpha_4\beta_7$ Integrin Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:159-163.	
	78.	Chen, L. et al. (2000). " <i>N</i> -Acyl Phenylalanine Analogues as Potent Small Molecule VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 10:725-727.	
	79.	Chen, L. et al. (2000). " <i>N</i> -Benzylpyroglutamyl-L-phenylalanine Derivatives as VCAM/VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 10:729-733.	
	80.	Chen, L. et al. (2002). "Focused Library Approach for Identification of New <i>N</i> -Acylphenylalanines as VCAM/VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:1679-1682.	
	81.	Chen, L. et al. (2002). " <i>N</i> -Acyl-L-phenylalanine Derivatives as Potent VLA-4 Antagonists that Mimic a Cyclic Peptide Conformation," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:137-140.	
	82.	Chen, M-H. et al. (1999). "Carbohydroxamido-Oxazolidines: Antibacterial Agents That Target Lipid A Biosynthesis," <i>Bioorg. & Med. Chem. Letts.</i> 9(3):313-318.	
	83.	Clements, J.M. et al. (2002). "Antibacterial Activities and Characterization of Novel Inhibitors of LpxC," <i>Antimicrobial Agents and Chemotherapy.</i> 46(6):1793-1799.	
	84.	Cromwell, N.H. et al. (1979). "The Azetidines. Recent Synthetic Developments." <i>Chemical Reviews</i> 79(4): 331-358.	
	85.	de Laszlo, S.E. et al. (2002). "Identification of Unique VLA-4 Antagonists from a Combinatorial Library," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:685-688.	
	86.	Doherty, G.A. et al. (2002). " <i>N</i> -Aryl 2,6-Dimethoxybiphenylalanine Analogues as VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:729-731.	
	87.	Doherty, G.A. et al. (2002). "Substituted Tetrahydrofuroyl-1-phenylalanine Derivatives as Potent and Specific VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:1501-1505.	
	88.	Dubree, N.J.P. et al. (2002). "Selective $\alpha_4\beta_7$ Integrin Antagonists and Their Potential as Antiinflammatory Agents," <i>J. Med. Chem.</i> 45(16):3451-3457.	
	89.	Duggan, M.E. et al. (2000). "Nonpeptide $\alpha_4\beta_3$ Antagonists. 1. Transformation of a Potent, Integrin-Selective $\alpha_{11b}\beta_3$ Antagonist into a Potent $\alpha_4\beta_3$ Antagonist," <i>J. Med. Chem.</i> 43:3736-3745.	
	90.	Feuston, B.P. (2002). "Binding Model for Nonpeptide Antagonists of $\alpha_4\beta_3$ Integrin," <i>Journal of Medicinal Chemistry</i> 45(26):5640-5648.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92) pa- 809751		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 342312004800	Application Number 10/617,616
		Applicant <div style="text-align: center;">Bore G. RAJU et al</div>	
		Filing Date July 11, 2003	Group Art Unit Not Yet Assigned
		Mailing Date March 8, 2004	
	91.	Fotouhi, N. et al. (2000). "Cyclic Thioether Peptide Mimetics as VCAM-VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 10:1167-1169.	
	92.	Fotouhi, N. et al. (2000). "The Design and Synthesis of Potent Cyclic Peptide VCAM-VLA-4 Antagonists Incorporating an Achiral Asp-Pro Mimetic," <i>Bioorganic & Medicinal Chemistry Letters</i> 10:1171-1173.	
	93.	Gadek, T.R. et al. (2002). "Generation of an LFA-1 Antagonist by the Transfer of the ICAM-1 Immunoregulatory Epitope to a Small Molecule," <i>Science</i> 295:1086-1089.	
	94.	Goodman, S.L. et al. (2002). "Nanomolar Small Molecule Inhibitors for $\alpha\beta6$, $\alpha\beta5$, and $\alpha\beta3$ Integrins," <i>J. Med. Chem.</i> 45(5):1045-1051.	
	95.	Hagmann, W.K. et al. (2001). "The Discovery of Sulfonylated Dipeptides as Potent VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 11:2709-2713.	
	96.	Huth, J.R. et al. (2000). "NMR and Mutagenesis Evidence for an I Domain Allosteric Site That Regulates Lymphocyte Function-Associated Antigen 1 Ligand Binding," <i>PNAS</i> 97(10):5231-5236.	
	97.	Hyland, S.A. et al. (1997). "Cloning, Expression, and Purification of UDP-3-O-Acyl-GlcNAc Deacetylase from <i>Pseudomonas aeruginosa</i> : A Metalloamidase of the Lipid A Biosynthesis Pathway," <i>J. Bacteriology</i> 179(6): 2029-2037.	
	98.	Inagawa, T. et al. (2001). "Defective Plasmid Partition in <i>ftsH</i> Mutants of <i>Escherichia coli</i> ," <i>Mol. Genet. Genomics</i> 265(5):755-762.	
	99.	Jackman, J.E. (1999). "Metal Ion Requirement and Inhibition of the UDP-3-O-acyl-GlcNAc Deacetylases of <i>Escherichia coli</i> and <i>Aquifex Aeolicus</i> ," <i>Dissertation Department of Biochemistry, Duke University</i> 203 pages.	
	100.	Jackman, J.E. et al. (1999). "UDP-3-O-(R-3-Hydroxymyristoyl)-N-acetylglucosamine Deacetylase of <i>Escherichia coli</i> Is a Zinc Metalloenzyme," <i>Biochemistry</i> 38(6):1902-1911.	
	101.	Jackman, J.E. et al. (2000). "Antibacterial Agents that Target Lipid A Biosynthesis in Gram-Negative Bacteria: Inhibition of Diverse UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine Deacetylases by Substrate Analogs Containing Zinc Binding Motifs," <i>J. Biol. Chem.</i> 275(15):11002-11009.	
	102.	Jackman, J.E. et al. (2001). "Site-Directed mutagenesis of the Bacterial Metalloamidase UDP-3-O-acyl)-N-acetylglucosamine Deacetylase (LpxC). Identification of the Zinc Binding Site," <i>Biochemistry</i> 40: 514-523.	
	103.	Kamenecka, T.M. et al. (2002). "N-Aryl-prolyl-dipeptides as Potent Antagonists of VLA-4," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:2205-2208.	
	104.	Kelly, T.A. et al. (1999). "Cutting Edge: A Small Molecule Antagonist of LFA-1-Mediated Cell Adhesion," <i>The Journal of Immunology</i> 163:5173-5177.	
	105.	Kline, T. et al. (2001). "Potent, Novel in Vitro Inhibitors of the <i>Pseudomonas aeruginosa</i> Deacetylase LpxC," <i>J. Med. Chem.</i> 45(14):3112-3129.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/08 (2-92) pa- 809751		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 342312004800	Application Number 10/617,616
		Applicant <div style="text-align: center;">Bore G. RAJU et al</div>	
		Filing Date July 11, 2003	Group Art Unit Not Yet Assigned
		Mailing Date March 8, 2004	
	106.	Kloser, A. et al. (1998) "Modulations in Lipid A and Phospholipid Biosynthesis Pathways Influence Outer Membrane Protein Assembly in <i>Escherichia coli</i> K-12," <i>Mol. Microbiol.</i> 27(5):1003-1008.	
	107.	Kloser, A.W. et al. (1996). " <i>asmB</i> , a Suppressor Locus for Assembly-Defective <i>OmpF</i> Mutants of <i>Escherichia coli</i> , Is Allelic to <i>envA</i> (<i>IpxC</i>)," <i>J. Bacteriol.</i> 178(17):5138-5143.	
	108.	Kobayashi, T. et al. (2002). "Convenient Synthesis of 3,3,3-Trifluoropropenyl Compounds from Aromatic Aldehydes by Means of the TBAF-Mediated Horner Reaction," <i>J. Org. Chem.</i> 67(9):3156-3159.	
	109.	Kopka, I.E. et al. (2002). "Substituted 3-Amino Biaryl Propionic Acids as Potent VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:2415-2418.	
	110.	Kopka, I.E. et al. (2002). "Substituted <i>N</i> -(3,5-Dichlorobenzenesulfonyl)-L-prolyl-phenylalanine Analogues as Potent VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:637-640.	
	111.	Lee, K-H. et al. (2002). "T Cell Receptor Signaling Precedes Immunological Synapse Formation," <i>Science</i> 295:1539-1542.	
	112.	Li, B. et al. (2002). " <i>N</i> -(Arylacetyl)-biphenylalanines as Potent VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:2141-2144.	
	113.	Li, X. et al. (2002). "Synthesis of a Carbohydrate-Derived Hydroxamic Acid Inhibitor of the Bacterial Enzyme (LpxC) Involved in Lipid A Biosynthesis," <i>Org. Lett.</i> 5(4):539-541.	
	114.	Lin, K-C. et al. (1998). "Very Late Antigen 4 (VLA4) Antagonists as Anti-Inflammatory Agents," <i>Current Opinion in Chemical Biology</i> 2:453-457.	
	115.	Lin, K-C. et al. (1999). "Selective, Tight-Binding Inhibitors of Integrin $\alpha 4 \beta 1$ That Inhibit Allergic Airway Responses," <i>J. Med. Chem.</i> 42:920-934.	
	116.	Lin, L.S. et al. (2002). "The Discovery of Acylated β -Amino Acids as Potent and Orally Bioavailable VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:611-614.	
	117.	Link, J.T. et al. (2001). "Discovery and SAR of Diarylsulfide Cyclopropylamide LFA-1/ICAM-1 Interaction Antagonist," <i>Bioorganic & Medicinal Chemistry Letters</i> 11:973-976.	
	118.	Liu, G. et al. (2000). "Discovery of Novel <i>p</i> -Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intracellular Adhesion Molecule-1 Interaction. 1. Identification of an Additional Binding Pocket Based on an Anilino Diaryl Sulfide Lead," <i>J. Med. Chem.</i> 43:4025-4040.	
	119.	Liu, G. et al. (2001). "Novel <i>p</i> -Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intracellular Adhesion Molecule-1 Interaction. 2. Mechanism of Inhibition and Structure-Based Improvement of Pharmaceutical Properties," <i>J. Med. Chem.</i> 44:1202-1210.	
	120.	Lu, T.T. et al. (2002). "Integrin-Mediated Long-Term B Cell Retention in the Splenic Marginal Zone," <i>Science</i> 297:409-412.	
	121.	Mousa, S.A. (2002). "Vitronectin Receptors in Vascular Disorders," <i>Current Opinion in Investigational Drugs</i> 3(8):1191-1195.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92) pa- 809751		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 342312004800	Application Number 10/617,616
		Applicant <div style="text-align: center;">Bore G. RAJU et al</div>	
		Filing Date July 11, 2003	Group Art Unit Not Yet Assigned
		Mailing Date March 8, 2004	
	122.	Müller, G. et al. (2001). "Discovery and Evaluation of Piperidinyl Carboxylic Acid Derivatives as Potent $\alpha_4\beta_1$ Integrin Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 11:3019-3021.	
	123.	Ogura, T. et al. (1999). "Balanced Biosynthesis of Major Membrane Components Through Regulated Degradation of the Committed Enzyme of Lipid A Biosynthesis by the AAA Protease FtsH (HflB) in <i>Escherichia coli</i> ," <i>Mol. Microbiol.</i> 31(3):833-844.	
	124.	Ohta, N. et al. (1999). "The Organellar Genomes of <i>Cyanidioschyzon merolae</i> ," <i>In Enigmatic Microorganisms and Life In Extreme Environments</i> , Seckbach, J. ed., Kluwer Academic Publishers: The Netherlands 1:141-149.	
	125.	Onishi, H.R. et al. (1996). "Antibacterial Agents That Inhibit Lipid A Biosynthesis," <i>Science</i> 274:980-982.	
	126.	Pei, Z. et al. (2001). "Discovery of Potent Antagonists of Leukocyte Function-Associated Antigen-1/Intercellular Adhesion Molecule-1 Interaction. 3. Amide (C-Ring) Structure-Activity Relationship and Improvement of Overall Properties of Arylthio Cinnamides," <i>J. Med. Chem.</i> 44:2913-2920.	
	127.	Pepinsky, R.B. et al. (2002). "Comparative Assessment of the Ligand and Metal Ion Binding Properties of Integrins $\alpha_9\beta_1$ and $\alpha_4\beta_1$," <i>Biochemistry</i> 41:7125-7141.	
	128.	Pirrung, M.C. et al. (2002). "Inhibition of the Antibacterial Target UDP-(3-O-acyl)-N-acetylglucosamine Deacetylase (LpxC): Isoxazoline Zinc Amidase Inhibitors Bearing Diverse Metal Binding Groups," <i>J. Med. Chem.</i> 45(19):4359-4370.	
	129.	Pirrung, M.C. et al. (2003). "High-Throughput Catch-and-Release Synthesis of Oxazoline Hydroxamates. Structure-Activity of <i>Escherichia coli</i> LpxC: In Vitro Enzyme Inhibition and Antibacterial Properties," <i>J. Am. Chem. Soc.</i> 125: 1575-1586.	
	130.	Pitts, W.J. et al. (2000). "Isoxazolines as Potent Antagonists of the Integrin $\alpha_4\beta_3$," <i>J. Med. Chem.</i> 43:27-40.	
	131.	Porter, J.R. et al. (2002). "N-(Pyrimidin-4-yl) and N-(Pyridin-2-yl) Phenylalanine Derivatives as VLA-4 Integrin Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:1595-1598.	
	132.	Porter, J.R. et al. (2002). "Squaric Acid Derivatives as VLA-4 Integrin Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:1051-1054.	
	133.	Porter, J.R. et al. (2003). "Dehydrophenylalanine Derivatives as VLA-4 Integrin Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 13:805-808.	
	134.	Price, N.P. et al. (1994). "Biosynthesis of a Structurally Novel Lipid A in <i>Rhizobium leguminosarum</i> : Identification and Characterization of Six Metabolic Steps Leading From UDP-GlcNAc to 3-Deoxy-D-manno-2-Octulosonic Acid ₂ -Lipid IV _A ," <i>J. Bacteriol.</i> 176(15):4646-4655.	
	135.	Qiu, X-L. et al. (2000). "Practical Synthesis of Boc-Protected <i>cis</i> -4-Trifluoromethyl and <i>cis</i> -4-Difluoromethyl-L- prolines," <i>J. Org. Chem.</i> 67:7162-7164.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92) pa- 809751		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 342312004800	Application Number 10/617,616
		Applicant <div style="text-align: center;">Bore G. RAJU et al</div>	
		Filing Date July 11, 2003	Group Art Unit Not Yet Assigned
		Mailing Date March 8, 2004	
	136.	Raetz, C.R.H. (1998). "Enzymes of Lipid A Biosynthesis: Targets for the Design of New Antibiotics," <i>In Endotoxins and Sepsis: Molecular Mechanisms of Pathogenesis, Host Resistances, and Therapy</i> J. Levin et al. eds., Wiley-Liss: New York, NY pp. 1-14.	
	137.	Raetz, C.R.H. (1996). "Bacterial Lipopolysaccharides: A Remarkable Family of Bioactive Macroamphiphiles" Chapter 69 <i>In Escherichia coli and Salmonella: Cellular and Molecular Biology</i> Second Edition, Neidhardt, F.C. ed., ASM Press: Materials Park, OH Vol. I, pp. 1035-1063.	
	138.	Rodebaugh, R.M. et al. (1971). "2-Carboazetidine Derivatives (1)," <i>J. Heterocycl. Chem.</i> 8:19-24.	
	139.	Scozzafava, A. et al. (2002). "Carbonic Anhydrase Activators: High Affinity Isozymes I, II, and IV Activators, Incorporating a β -Alanyl-Histidine Scaffold," <i>J. Med. Chem.</i> 45(2):284-291.	
	140.	Sekikawa, I. et al. (1983). "Synthesis of Isonipicotinoyl Analogues of Aminopterin and Folic Acid," <i>J. Heterocyclic Chem.</i> 20:807-809.	
	141.	Sidduri, A. et al. (2002). "N-Aroyl-L-Phenylalanine Derivatives as VCAM/VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:2479-2482.	
	142.	Sidduri, A. et al. (2002). "N-Cycloalkanoyl-L-Phenylalanine Derivatives as VCAM/VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:2475-2478.	
	143.	Singh, J. et al. (2002). "Identification of Potent and Novel $\alpha 4 \beta 1$ Antagonists Using in Silico Screening," <i>J. Med. Chem.</i> 45:2988-2993.	
	144.	Sorensen, P.G. et al. (1996). "Regulation of USP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine Deacetylase in <i>Escherichia coli</i> . The Second Enzymatic Step of Lipid A Biosynthesis," <i>J. Biol. Chem.</i> 271(42):25898-25905.	
	145.	Su, T. et al. (1997). "Fibrinogen Receptor (GPIIb-IIIa) Antagonists Derived from 5,6-Bicyclic Templates. Amidinoindoles, Amidinoindazoles, and Amidinobenzofurans Containing the N- α -Sulfonamide Carboxylic Acid Function as Potent Platelet Aggregation Inhibitors," <i>J. Med. Chem.</i> 40:4308-4318.	
	146.	Sutherland, P.J. et al. (1998) "Dictyostelium discoideum Fatty-acyl Amidase II Has Deacylase Activity on <i>Rhizobium</i> Nodulation Factors," <i>J. Biol. Chem.</i> 273(8):4459-4464.	
	147.	Tilley, J. et al. (2000). "Carbacyclic Peptide Mimetics as VCAM-VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 10:1163-1165.	
	148.	Tilley, J.W. et al. (2001). "Imide and Lactam Derivatives of N-Benzylpyroglutamyl-L-phenylalanine as VCAM/VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 11:1-4.	
	149.	Tumey, L.N. et al. (2001). "Parallel Synthesis of Lipid A Biosynthesis Inhibitors," <i>Abstracts of Papers, Part 2: 222nd ACS National Meeting</i> : Chicago, IL, August 26-30, 2001. Abstract No. 623, one page.	
	150.	Vaara, M. (1996). "Lipid A: Target for Antibacterial Drugs," <i>Science</i> 274: 939-940.	
	151.	van der Merwe, P.A. et al. (2002). "The Immunological Synapse - a Multitasking System," <i>Science</i> 295:1479-1480.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92) pa- 809751		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 342312004800	Application Number 10/617,616
	Applicant Bore G. RAJU et al	
	Filing Date July 11, 2003	Group Art Unit Not Yet Assigned
	Mailing Date March 8, 2004	

152.	Wang et al. (2001). "A Fluorescence-Based Homogeneous Assay for Measuring Activity of UDP-3-O-(R-3-Hydroxymyristoyl)-N-acetylglucosamine Deacetylase." <i>Analytical Biochem.</i> 290: 338-346.
153.	Wattanasin, S. et al. (2001). "Design and Synthesis of Potent and Selective Inhibitors of Integrin VLA-4," <i>Bioorganic & Medicinal Chemistry Letters</i> 11:2955-2958.
154.	Wehner, V. et al. (2002). "Aromatic β -Amino Acids as Asp-Phg Mimics in LDV Derived VLA-4 Antagonists," <i>Synthesis</i> 14:2023-2036.
155.	Wei, Y. et al. (2001). "Global Impact of <i>sdiA</i> Amplification Revealed by Comprehensive Gene Expression Profiling of <i>Escherichia coli</i> ," <i>J. Bacteriol.</i> 183(7): 2265-2272.
156.	Weitz-Schmidt, G. et al. (2001). "Statins Selectively Inhibit Leukocyte Function Antigen-1 by Binding to a Novel Regulatory Integrin Site," <i>Nature Medicine</i> 7(6):687-692.
157.	Welsenbach, K. et al. (2002). "Small Molecule Inhibitors Induce Conformational Changes in the I Domain and the I-like Domain of Lymphocyte Function-Associated Antigen-1," <i>The Journal of Biological Chemistry</i> 277(12):10590-10598.
158.	Winn, M. et al. (2001). "Discovery of Novel p-Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intercellular Adhesion Molecule-1 Interaction. 4. Structure-Activity Relationship of Substituents on the Benzene Ring of the Cinnamide," <i>J. Med. Chem.</i> 44:4393-4403.
159.	Yang, G.X. et al. (2002). "N-Tetrahydrofuroyl-(L)-Phenylalanine Derivatives as Potent VLA-4 Antagonists," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:1497-1500.
160.	Young, K. et al. (1995). "The <i>envA</i> Permeability/Cell Division Gene of <i>Escherichia coli</i> Encodes the Second Enzyme of Lipid A Biosynthesis. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase," <i>J. Biol. Chem.</i> 270(51):30384-30391.
161.	Zimmerman, C.N. (1999). "Peptide and Peptidomimetic Inhibitors of VLA-4," <i>Expert Opinion on Therapeutic Patents</i> 9(2):129-133.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.